Corteva Inc. Common Stock vs Heron Therapeutics Inc — how do they compare? Corteva Inc. Common Stock trades at $13.38 (market cap $9.17B), while Heron Therapeutics Inc trades at $0.39 (market cap $68.01M). The key difference: Corteva Inc. Common Stock is far larger — about 134.8× Heron Therapeutics Inc's market cap, and Corteva Inc. Common Stock pays a 5.24% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corteva Inc. Common Stock for 0 Days and Heron Therapeutics Inc for 35 Days on average.
| CTVA | HRTX | |
|---|---|---|
Market Cap | $9.17B | $68.01M |
Volume | 35,183,471 | 1,891,941 |
Sector | Basic Materials | Health |
52-Week High | $90.51 | $1.49 |
52-Week Low | $11.92 | $0.27 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $11.68B | $174.75M |
Dividend Yield | 5.24% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Corteva provides seeds, crop protection products, and digital tools for agriculture. Its products are used by farmers to manage crop production and protect yields.
Read more on CTVA →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →